Leadership Overview
Revance Therapeutics has 7 executives leading key functions including strategy, technology, operations, finance, human resources, revenue, and legal.
Focused on advancing novel botulinum toxin products, Revance Therapeutics drives innovation in aesthetic and therapeutic markets to improve patient outcomes through rigorous clinical development and commercial excellence.
Focused on advancing novel botulinum toxin products, Revance Therapeutics drives innovation in aesthetic and therapeutic markets to improve patient outcomes through rigorous clinical development and commercial excellence.
Leadership Roles at Revance Therapeutics
Nadeem Moiz - Chief Executive Officer
Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the overarching corporate strategy and long-term vision for the biotechnology firm. By overseeing the development and commercialization of DaxibotulinumtoxinA, Moiz ensures the organization maintains a competitive edge in the aesthetic and therapeutic markets. This leadership role involves constant collaboration with the Board to align clinical trial milestones with investor expectations and market demands. Nadeem Moiz manages the transition of drug candidates from Phase III clinical trials toward full-scale manufacturing and market entry. Through precise resource allocation and high-level decision-making, the Chief Executive Officer fosters a culture of scientific rigor and operational efficiency. By prioritizing the advancement of the RT002 pipeline, the executive secures the future growth trajectory of the company while navigating complex regulatory landscapes across North American and global markets.
Scott Leffler - Chief Financial Officer
Scott Leffler, the Chief Financial Officer at Revance Therapeutics, directs the financial planning, capital allocation, and fiscal reporting functions for the biotechnology enterprise. Overseeing the budgeting process for extensive Phase III clinical trials, the Chief Financial Officer ensures the company maintains the necessary liquidity to fund ongoing research and development for RT002 and RT001. This role involves managing investor relations and communicating the financial impact of clinical milestones to stakeholders. Scott Leffler drives the development of long-term financial models that support the company's expansion into new aesthetic and therapeutic indications. By monitoring market trends and managing financial risks, the executive provides the stability required for sustained innovation. Through rigorous oversight of the balance sheet and capital structure, Leffler enables the organization to pursue its strategic goals, ensuring that financial resources remain effectively deployed to maximize shareholder value and support the company's mission.
Nicholas Crowe - Chief Operating Officer
Nicholas Crowe, the Chief Operating Officer at Revance Therapeutics, manages the day-to-day operational execution of the company's manufacturing and supply chain strategies. Overseeing the production logistics for botulinum toxin products, the Chief Operating Officer ensures that clinical trial supply requirements meet strict timelines and quality benchmarks. This leadership role involves coordinating with internal research teams to streamline the transition from laboratory development to commercial-scale manufacturing. Nicholas Crowe drives operational excellence by identifying bottlenecks in the production cycle and implementing process improvements that increase efficiency. By maintaining robust oversight of the company's operational footprint, the executive supports the successful delivery of therapeutic solutions to the market. Through meticulous planning and resource management, Crowe ensures that the organization remains agile in responding to shifting clinical needs, ultimately facilitating the seamless execution of the company's broader business objectives and long-term growth strategies.
Satish Kalala - Chief Technology Officer
Satish Kalala, the Chief Technology Officer at Revance Therapeutics, architects the digital and technical infrastructure supporting the company's complex biotechnology research and manufacturing processes. Overseeing the integration of advanced data analytics into clinical trial workflows, the Chief Technology Officer ensures the integrity and accessibility of critical research findings for DaxibotulinumtoxinA. This role involves managing the technological systems that track preclinical development for the topical gel candidate, RT001. Satish Kalala drives the implementation of secure, scalable platforms that facilitate cross-departmental collaboration between research teams and manufacturing facilities. By optimizing technical operations, the executive enhances the speed and accuracy of data-driven decision-making across the organization. Through the deployment of cutting-edge software solutions, Kalala supports the company's mission to deliver innovative medical products, ensuring that all technological assets remain aligned with the rigorous standards required for pharmaceutical development and commercial success.
Matthew Argano - Chief Human Resources Officer
Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, architects the talent acquisition and organizational development strategies necessary to support a high-growth biotechnology firm. Overseeing the recruitment of specialized scientific and commercial talent, the Chief Human Resources Officer ensures the company maintains a workforce capable of executing complex clinical trials and product launches. This role involves designing performance management systems that align individual contributions with the company's core mission of delivering novel botulinum toxin products. Matthew Argano drives initiatives focused on employee engagement, leadership development, and corporate culture to retain top-tier expertise in a competitive industry. By fostering an environment of innovation and accountability, the executive supports the operational needs of the entire organization. Through the implementation of strategic human capital programs, Argano ensures that the company possesses the internal capabilities required to navigate the challenges of the pharmaceutical market and achieve long-term success.
Steven Kreider - Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics
Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, directs the commercial strategy and revenue generation efforts for the company's portfolio. Overseeing the market launch and sales initiatives for DaxibotulinumtoxinA, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics ensures that the product reaches key aesthetic and therapeutic providers across the country. This role involves building and managing high-performing sales teams that communicate the clinical benefits of the company's offerings to medical professionals. Steven Kreider drives the development of pricing and distribution strategies that maximize market penetration and revenue growth. By analyzing market data and competitor activity, the executive identifies new opportunities for expansion within the aesthetic and therapeutic sectors. Through the execution of targeted commercial campaigns, Kreider ensures that the company's innovative products achieve widespread adoption, directly contributing to the organization's financial performance and market leadership.
Kira Schwartz - Chief Legal Officer
Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, directs the legal, compliance, and intellectual property strategies for the biotechnology firm. Overseeing the protection of the company's proprietary botulinum toxin technologies, the Chief Legal Officer ensures that all research and commercial activities adhere to complex regulatory requirements. This role involves managing patent portfolios, negotiating strategic partnerships, and providing counsel on corporate governance matters. Kira Schwartz drives the development of robust compliance frameworks that mitigate legal risks associated with clinical trials and product marketing. By navigating the intricate legal landscape of the pharmaceutical industry, the executive safeguards the company's assets and reputation. Through proactive legal oversight, Schwartz supports the organization's ability to innovate and bring new therapies to market, ensuring that all business operations remain consistent with legal standards and ethical practices while facilitating the company's long-term strategic objectives.
Explore Leadership Teams in Manufacturing
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company is headquartered in Tokyo, Japan
Company Leadership KS
AP
AM
SS
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Company Leadership
AB
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership LP
RV
SA
MT
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Frequently Asked Questions Regarding Revance Therapeutics Top Executives and Leadership Team
